JP2021518395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021518395A5 JP2021518395A5 JP2020550667A JP2020550667A JP2021518395A5 JP 2021518395 A5 JP2021518395 A5 JP 2021518395A5 JP 2020550667 A JP2020550667 A JP 2020550667A JP 2020550667 A JP2020550667 A JP 2020550667A JP 2021518395 A5 JP2021518395 A5 JP 2021518395A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- oxo
- amino
- thio
- pyrazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 naphthalene-1-yl group Chemical group 0.000 claims 171
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 13
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 7
- LPCQBTAOTIZGAE-UHFFFAOYSA-N 2h-pyrimidine-1-carboxamide Chemical compound NC(=O)N1CN=CC=C1 LPCQBTAOTIZGAE-UHFFFAOYSA-N 0.000 claims 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 4
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 2
- XQXXOWKUJRCUGZ-UHFFFAOYSA-N (4-methylpiperidin-4-yl)methanamine Chemical compound NCC1(C)CCNCC1 XQXXOWKUJRCUGZ-UHFFFAOYSA-N 0.000 claims 1
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 1
- IBHIUPPGDYCBSV-UHFFFAOYSA-N 1,2-dihydroimidazol-5-one Chemical compound O=C1NCN=C1 IBHIUPPGDYCBSV-UHFFFAOYSA-N 0.000 claims 1
- SCDFILPFVOPDMQ-UHFFFAOYSA-N 1-(3-aminocyclohexyl)-4-(2,3-dichlorophenyl)pyridin-2-one Chemical compound NC1CC(CCC1)N1C(C=C(C=C1)C1=C(C(=CC=C1)Cl)Cl)=O SCDFILPFVOPDMQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 1
- IFOXEIWAOZTLPH-APPDUMDISA-N 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichloroanilino)-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1NC(C2=C(N=1)NC=C2NC1=C(C(=CC=C1)Cl)Cl)=O)C IFOXEIWAOZTLPH-APPDUMDISA-N 0.000 claims 1
- KKVLZJPXYUIIIF-KPZWWZAWSA-N 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichloroanilino)-3-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1N(C(C2=C(N=1)NC=C2NC1=C(C(=CC=C1)Cl)Cl)=O)C)C KKVLZJPXYUIIIF-KPZWWZAWSA-N 0.000 claims 1
- AFVYHLNMSBZECS-KPZWWZAWSA-N 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenoxy)-3-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1N(C(C2=C(N=1)NC=C2OC1=C(C(=CC=C1)Cl)Cl)=O)C)C AFVYHLNMSBZECS-KPZWWZAWSA-N 0.000 claims 1
- NRTBXUFMVUIAAD-UHFFFAOYSA-N 2-[4-(aminomethyl)-4-methylpiperidin-1-yl]-5-(2,3-dichlorophenyl)-1-methyl-6-oxopyrimidine-4-carbonitrile Chemical compound NCC1(CCN(CC1)C=1N(C(C(=C(N=1)C#N)C1=C(C(=CC=C1)Cl)Cl)=O)C)C NRTBXUFMVUIAAD-UHFFFAOYSA-N 0.000 claims 1
- PFWXRXTXRFAYGY-UHFFFAOYSA-N 2-[4-(aminomethyl)-4-methylpiperidin-1-yl]-5-(2,3-dichlorophenyl)sulfanyl-3H-pyrido[3,4-d]pyrimidin-4-one Chemical compound NCC1(CCN(CC1)C=1NC(C2=C(N=1)C=NC=C2SC1=C(C(=CC=C1)Cl)Cl)=O)C PFWXRXTXRFAYGY-UHFFFAOYSA-N 0.000 claims 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 1
- SYWOGGKKFGSXNS-UHFFFAOYSA-N 3-(2-aminospiro[bicyclo[3.1.0]hexane-3,4'-piperidine]-1'-yl)-6-(2,3-dichlorophenyl)sulfanyl-1-methylpyrazin-2-one Chemical compound NC1C2CC2CC11CCN(CC1)C=1C(N(C(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)C)=O SYWOGGKKFGSXNS-UHFFFAOYSA-N 0.000 claims 1
- CBTBEOJTLGXQBZ-UHFFFAOYSA-N 3-(4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(2,3-dichlorophenyl)sulfanyl-1-methylpyrazin-2-one Chemical compound NC1COCC11CCN(CC1)C=1C(N(C(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)C)=O CBTBEOJTLGXQBZ-UHFFFAOYSA-N 0.000 claims 1
- OQJHFEOXMDSFMI-UHFFFAOYSA-N 3-(4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl)-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound NC1COCC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O OQJHFEOXMDSFMI-UHFFFAOYSA-N 0.000 claims 1
- TVNBISXYSAIDKO-UHFFFAOYSA-N 3-(6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound NC1C2CN(CC12)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O TVNBISXYSAIDKO-UHFFFAOYSA-N 0.000 claims 1
- UJRCFTNATREODD-OAQYLSRUSA-N 3-[(1S)-1-amino-4-methoxyspiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1C2=CC=CC(=C2CC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O)OC UJRCFTNATREODD-OAQYLSRUSA-N 0.000 claims 1
- UNRCWEPFQCACOS-HXUWFJFHSA-N 3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1C2=CC=CC=C2CC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O UNRCWEPFQCACOS-HXUWFJFHSA-N 0.000 claims 1
- QUDYOUIUXBQJBP-XJKSGUPXSA-N 3-[(2R,4R)-4-amino-2-methyl-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)sulfanyl-1-methylpyrazin-2-one Chemical compound N[C@@H]1C[C@@H](CC11CCN(CC1)C=1C(N(C(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)C)=O)C QUDYOUIUXBQJBP-XJKSGUPXSA-N 0.000 claims 1
- KUOXDSAASAJNGS-IINYFYTJSA-N 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichloropyridin-4-yl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=NC=C1)Cl)Cl)=O)C KUOXDSAASAJNGS-IINYFYTJSA-N 0.000 claims 1
- NXGCMWDNLSXJON-MEDUHNTESA-N 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2-chloro-3-fluorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)F)Cl)=O)C NXGCMWDNLSXJON-MEDUHNTESA-N 0.000 claims 1
- CDCDRNUWELNRQH-XHDPSFHLSA-N 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(3-chloro-1-methyl-2-oxopyridin-4-yl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(N(C=C1)C)=O)Cl)=O)C CDCDRNUWELNRQH-XHDPSFHLSA-N 0.000 claims 1
- FGOMPCFISFVIAW-XHDPSFHLSA-N 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(3-chloro-2-methoxypyridin-4-yl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=NC=C1)OC)Cl)=O)C FGOMPCFISFVIAW-XHDPSFHLSA-N 0.000 claims 1
- SXRNTXDHSFPIIM-IINYFYTJSA-N 3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-[(3-chloro-2-oxo-1H-pyridin-4-yl)sulfanyl]-1H-pyrazin-2-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(NC=C1)=O)Cl)=O)C SXRNTXDHSFPIIM-IINYFYTJSA-N 0.000 claims 1
- ILPTXIJRMXVQQY-CYBMUJFWSA-N 3-[(4R)-4-amino-2,2-difluoro-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1CC(CC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O)(F)F ILPTXIJRMXVQQY-CYBMUJFWSA-N 0.000 claims 1
- SIULRGIDMNPONH-SBXXRYSUSA-N 3-[(4R)-4-amino-2-fluoro-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1CC(CC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O)F SIULRGIDMNPONH-SBXXRYSUSA-N 0.000 claims 1
- OQJHFEOXMDSFMI-ZDUSSCGKSA-N 3-[(4R)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@H]1COCC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O OQJHFEOXMDSFMI-ZDUSSCGKSA-N 0.000 claims 1
- YGFOFLRRLIUMBV-CQSZACIVSA-N 3-[(4R)-4-amino-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1CCCC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O YGFOFLRRLIUMBV-CQSZACIVSA-N 0.000 claims 1
- OQJHFEOXMDSFMI-CYBMUJFWSA-N 3-[(4S)-4-amino-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1COCC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O OQJHFEOXMDSFMI-CYBMUJFWSA-N 0.000 claims 1
- VFNBGRKGBQBPJF-LJQANCHMSA-N 3-[(5S)-5-aminospiro[5,7-dihydrocyclopenta[b]pyridine-6,4'-piperidine]-1'-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1C=2C(=NC=CC=2)CC11CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O VFNBGRKGBQBPJF-LJQANCHMSA-N 0.000 claims 1
- DXEIVWFORALKLE-SNVBAGLBSA-N 3-[(6R)-6-amino-2-azaspiro[3.4]octan-2-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@H]1CC2(CN(C2)C=2C(NC(=CN=2)SC2=C(C(=CC=C2)Cl)Cl)=O)CC1 DXEIVWFORALKLE-SNVBAGLBSA-N 0.000 claims 1
- DXEIVWFORALKLE-JTQLQIEISA-N 3-[(6S)-6-amino-2-azaspiro[3.4]octan-2-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound N[C@@H]1CC2(CN(C2)C=2C(NC(=CN=2)SC2=C(C(=CC=C2)Cl)Cl)=O)CC1 DXEIVWFORALKLE-JTQLQIEISA-N 0.000 claims 1
- CUCPROKEXAIMCC-UHFFFAOYSA-N 3-[3-(aminomethyl)-3-methylpyrrolidin-1-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound NCC1(CN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O)C CUCPROKEXAIMCC-UHFFFAOYSA-N 0.000 claims 1
- LNZNZGGVJFERLM-UHFFFAOYSA-N 3-[4-(aminomethyl)-4-fluoropiperidin-1-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound NCC1(CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O)F LNZNZGGVJFERLM-UHFFFAOYSA-N 0.000 claims 1
- WHUNDUIZDAWWGK-UHFFFAOYSA-N 3-[4-(aminomethyl)-4-hydroxypiperidin-1-yl]-6-(2,3-dichlorophenyl)sulfanyl-1H-pyrazin-2-one Chemical compound NCC1(CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)Cl)Cl)=O)O WHUNDUIZDAWWGK-UHFFFAOYSA-N 0.000 claims 1
- NAKPYWCEFBAGEU-UHFFFAOYSA-N 3-[4-(aminomethyl)-4-methylpiperidin-1-yl]-6-(2,3-dichlorophenyl)-1H-pyrazin-2-one Chemical compound NCC1(CCN(CC1)C=1C(NC(=CN=1)C1=C(C(=CC=C1)Cl)Cl)=O)C NAKPYWCEFBAGEU-UHFFFAOYSA-N 0.000 claims 1
- HAAAXABVIGQBOT-UHFFFAOYSA-N 3-[4-(aminomethyl)-4-methylpiperidin-1-yl]-6-(2-chloro-3-methoxyphenyl)sulfanyl-1H-pyrazin-2-one Chemical compound NCC1(CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=CC=C1)OC)Cl)=O)C HAAAXABVIGQBOT-UHFFFAOYSA-N 0.000 claims 1
- IGWAIPLFFIMTAQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-4-methylpiperidin-1-yl]-6-(3-chloro-2-methoxypyridin-4-yl)sulfanyl-1H-pyrazin-2-one Chemical compound NCC1(CCN(CC1)C=1C(NC(=CN=1)SC1=C(C(=NC=C1)OC)Cl)=O)C IGWAIPLFFIMTAQ-UHFFFAOYSA-N 0.000 claims 1
- VCHHVKLUGGQAET-UHFFFAOYSA-N 3-[4-(aminomethyl)-4-methylpiperidin-1-yl]-6-[2-(trifluoromethyl)phenyl]sulfanyl-1H-pyrazin-2-one Chemical compound NCC1(CCN(CC1)C=1C(NC(=CN=1)SC1=C(C=CC=C1)C(F)(F)F)=O)C VCHHVKLUGGQAET-UHFFFAOYSA-N 0.000 claims 1
- SVRUKQKRAHSRTQ-UHFFFAOYSA-N 3-[4-(aminomethyl)-4-methylpiperidin-1-yl]-6-[2-(trifluoromethyl)pyridin-3-yl]sulfanyl-1H-pyrazin-2-one Chemical compound NCC1(CCN(CC1)C=1C(NC(=CN=1)SC=1C(=NC=CC=1)C(F)(F)F)=O)C SVRUKQKRAHSRTQ-UHFFFAOYSA-N 0.000 claims 1
- VGNPATCUBXRDBE-UHFFFAOYSA-N 3-[4-(aminomethyl)-4-methylpiperidin-1-yl]-6-naphthalen-1-ylsulfanyl-1H-pyrazin-2-one Chemical compound NCC1(CCN(CC1)C=1C(NC(=CN=1)SC1=CC=CC2=CC=CC=C12)=O)C VGNPATCUBXRDBE-UHFFFAOYSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- SQDOXGXCLKGIAT-UHFFFAOYSA-N 4-amino-2-(6-amino-2-azaspiro[3.4]octan-2-yl)-5-(2,3-dichlorophenyl)sulfanyl-1H-pyrimidin-6-one Chemical compound NC1=C(C(NC(=N1)N1CC2(C1)CC(CC2)N)=O)SC1=C(C(=CC=C1)Cl)Cl SQDOXGXCLKGIAT-UHFFFAOYSA-N 0.000 claims 1
- FGTDIEOPGHWZOR-UHFFFAOYSA-N 4-amino-2-(6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-5-(2,3-dichlorophenyl)sulfanyl-1H-pyrimidin-6-one Chemical compound NC1=C(C(NC(=N1)N1CC2C(C2C1)N)=O)SC1=C(C(=CC=C1)Cl)Cl FGTDIEOPGHWZOR-UHFFFAOYSA-N 0.000 claims 1
- MGSZQRPSSXLWIN-UHFFFAOYSA-N 4-amino-2-(6-amino-3-azabicyclo[3.2.0]heptan-3-yl)-5-(2,3-dichlorophenyl)sulfanyl-1H-pyrimidin-6-one Chemical compound NC1=C(C(NC(=N1)N1CC2CC(C2C1)N)=O)SC1=C(C(=CC=C1)Cl)Cl MGSZQRPSSXLWIN-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- IQVNXICBINOVNT-UHFFFAOYSA-N 5-[1-(1-aminopropan-2-yl)piperidin-4-yl]-3-(2,3-dichlorophenyl)sulfanyl-1,6-dihydropyrazolo[4,3-d]pyrimidin-7-one Chemical compound NCC(C)N1CCC(CC1)C=1NC(C2=C(N=1)C(=NN2)SC1=C(C(=CC=C1)Cl)Cl)=O IQVNXICBINOVNT-UHFFFAOYSA-N 0.000 claims 1
- QEESQKCQMWEXCC-UHFFFAOYSA-N 6-(2,3-dichlorophenyl)sulfanyl-3-(piperidin-4-ylamino)-1H-pyrazin-2-one Chemical compound ClC1=C(C=CC=C1Cl)SC1=CN=C(C(N1)=O)NC1CCNCC1 QEESQKCQMWEXCC-UHFFFAOYSA-N 0.000 claims 1
- OYYXDXFCUKNPSW-UHFFFAOYSA-N 6-(2-amino-3-chloropyridin-4-yl)sulfanyl-3-[4-(aminomethyl)-4-methylpiperidin-1-yl]-1H-pyrazin-2-one Chemical compound NC1=NC=CC(=C1Cl)SC1=CN=C(C(N1)=O)N1CCC(CC1)(C)CN OYYXDXFCUKNPSW-UHFFFAOYSA-N 0.000 claims 1
- PNLMLGLYVFMTEO-UHFFFAOYSA-N 6-(5-amino-2-chlorophenyl)sulfanyl-3-[4-(aminomethyl)-4-methylpiperidin-1-yl]-1H-pyrazin-2-one Chemical compound NC=1C=CC(=C(C=1)SC1=CN=C(C(N1)=O)N1CCC(CC1)(C)CN)Cl PNLMLGLYVFMTEO-UHFFFAOYSA-N 0.000 claims 1
- BRGIDJLKNGSBSX-MEDUHNTESA-N 6-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichloroanilino)-4-methyl-2H-pyrazolo[3,4-b]pyrazin-5-one Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(N(C2=C(N=1)NN=C2NC1=C(C(=CC=C1)Cl)Cl)C)=O)C BRGIDJLKNGSBSX-MEDUHNTESA-N 0.000 claims 1
- MSOFATSUYQHEEW-UHFFFAOYSA-N 6-[3-(aminomethyl)-3-methylpyrrolidin-1-yl]-3-(2,3-dichlorophenoxy)-2,5-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical compound NCC1(CN(CC1)C=1NC(C2=C(N=1)NN=C2OC1=C(C(=CC=C1)Cl)Cl)=O)C MSOFATSUYQHEEW-UHFFFAOYSA-N 0.000 claims 1
- MXRKHCMUIGDXSN-UHFFFAOYSA-N 6-[3-(aminomethyl)-3-methylpyrrolidin-1-yl]-3-(2,3-dichlorophenoxy)-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound NCC1(CN(CC1)C=1N(C(C2=C(N=1)NN=C2OC1=C(C(=CC=C1)Cl)Cl)=O)C)C MXRKHCMUIGDXSN-UHFFFAOYSA-N 0.000 claims 1
- NFJWKKZRQXOAOG-UHFFFAOYSA-N 6-[4-(aminomethyl)-4-methylpiperidin-1-yl]-3-(2,3-dichloroanilino)-2,5-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical compound NCC1(CCN(CC1)C=1NC(C2=C(N=1)NN=C2NC1=C(C(=CC=C1)Cl)Cl)=O)C NFJWKKZRQXOAOG-UHFFFAOYSA-N 0.000 claims 1
- QODGSQRBQDRZHQ-UHFFFAOYSA-N 6-[4-(aminomethyl)-4-methylpiperidin-1-yl]-3-[(2,3-dichlorophenyl)methyl]-2,5-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical compound NCC1(CCN(CC1)C=1NC(C2=C(N=1)NN=C2CC1=C(C(=CC=C1)Cl)Cl)=O)C QODGSQRBQDRZHQ-UHFFFAOYSA-N 0.000 claims 1
- WERJZUDNGGFTSX-UHFFFAOYSA-N 6-[4-(aminomethyl)-4-methylpiperidin-1-yl]-3-[1-(2,3-dichlorophenyl)ethyl]-5-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound NCC1(CCN(CC1)C=1N(C(C2=C(N=1)NN=C2C(C)C1=C(C(=CC=C1)Cl)Cl)=O)C)C WERJZUDNGGFTSX-UHFFFAOYSA-N 0.000 claims 1
- GWNJFXCSPJQYRL-UHFFFAOYSA-N 6-amino-2-(6-amino-2-azaspiro[3.4]octan-2-yl)-5-(2,3-dichlorophenyl)sulfanyl-3-methylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CC2(C1)CC(CC2)N)C)=O)SC1=C(C(=CC=C1)Cl)Cl GWNJFXCSPJQYRL-UHFFFAOYSA-N 0.000 claims 1
- VCGDQZBNGOXMBW-UHFFFAOYSA-N 6-amino-2-(6-amino-3-azabicyclo[3.1.0]hexan-3-yl)-5-(2,3-dichlorophenyl)sulfanyl-3-methylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CC2C(C2C1)N)C)=O)SC1=C(C(=CC=C1)Cl)Cl VCGDQZBNGOXMBW-UHFFFAOYSA-N 0.000 claims 1
- BPFQQNURHBZWDP-UHFFFAOYSA-N 6-amino-2-(6-amino-3-azabicyclo[3.2.0]heptan-3-yl)-5-(2,3-dichlorophenyl)sulfanyl-3-methylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CC2CC(C2C1)N)C)=O)SC1=C(C(=CC=C1)Cl)Cl BPFQQNURHBZWDP-UHFFFAOYSA-N 0.000 claims 1
- KAVXZROXVMILEK-UHFFFAOYSA-N 6-amino-2-[3-(aminomethyl)-3-methylpyrrolidin-1-yl]-5-(2,3-dichlorophenyl)sulfanyl-3-methylpyrimidin-4-one Chemical compound NC1=C(C(N(C(=N1)N1CC(CC1)(C)CN)C)=O)SC1=C(C(=CC=C1)Cl)Cl KAVXZROXVMILEK-UHFFFAOYSA-N 0.000 claims 1
- INCPGHMPWYLGBD-UHFFFAOYSA-N 7-amino-2-[4-(aminomethyl)-4-methylpiperidin-1-yl]-5-(2,3-dichlorophenyl)sulfanyl-3H-quinazolin-4-one Chemical compound NC1=CC(=C2C(NC(=NC2=C1)N1CCC(CC1)(C)CN)=O)SC1=C(C(=CC=C1)Cl)Cl INCPGHMPWYLGBD-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- WIFGMMMQZKSFRN-UHFFFAOYSA-N OC=1N=C2N(C(C=1C(=O)N)=O)C=CC=C2 Chemical compound OC=1N=C2N(C(C=1C(=O)N)=O)C=CC=C2 WIFGMMMQZKSFRN-UHFFFAOYSA-N 0.000 claims 1
- BKTUROGZJVHLON-UHFFFAOYSA-N OC=1N=C2N(C(C=1C(=O)N)=O)CCCC2 Chemical compound OC=1N=C2N(C(C=1C(=O)N)=O)CCCC2 BKTUROGZJVHLON-UHFFFAOYSA-N 0.000 claims 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 claims 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000004188 dichlorophenyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229930195733 hydrocarbon Natural products 0.000 claims 1
- 150000002430 hydrocarbons Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- USISRUCGEISZIB-UHFFFAOYSA-N piperidin-3-one Chemical compound O=C1CCCNC1 USISRUCGEISZIB-UHFFFAOYSA-N 0.000 claims 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646107P | 2018-03-21 | 2018-03-21 | |
| US62/646,107 | 2018-03-21 | ||
| PCT/US2019/022717 WO2019182960A1 (en) | 2018-03-21 | 2019-03-18 | Shp2 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518395A JP2021518395A (ja) | 2021-08-02 |
| JP2021518395A5 true JP2021518395A5 (https=) | 2021-09-09 |
| JP7265275B2 JP7265275B2 (ja) | 2023-04-26 |
Family
ID=67983388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550667A Active JP7265275B2 (ja) | 2018-03-21 | 2019-03-18 | Ｓｈｐ２阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10561655B2 (https=) |
| EP (1) | EP3768664B1 (https=) |
| JP (1) | JP7265275B2 (https=) |
| KR (1) | KR102724968B1 (https=) |
| CN (1) | CN112368272B (https=) |
| AU (1) | AU2019239658A1 (https=) |
| CA (1) | CA3097709A1 (https=) |
| RU (1) | RU2020133727A (https=) |
| TW (1) | TW201940167A (https=) |
| WO (1) | WO2019182960A1 (https=) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| TW201930292A (zh) * | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| JP7361693B2 (ja) | 2017-12-15 | 2023-10-16 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての多環式化合物 |
| IL276232B2 (en) | 2018-03-02 | 2024-04-01 | Otsuka Pharma Co Ltd | Pyrazine derivatives, pharmaceutical compositions comprising them and their use for treating diseases |
| AU2019240299B2 (en) | 2018-03-21 | 2023-06-22 | D.E. Shaw Research, Llc | SHP2 phosphatase inhibitors and methods of use thereof |
| US12138263B2 (en) | 2018-03-21 | 2024-11-12 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof |
| MX2020011528A (es) * | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
| MX2021000795A (es) | 2018-07-24 | 2021-04-12 | Taiho Pharmaceutical Co Ltd | Compuestos heterociclicos para inhibir la actividad de shp2. |
| CN112601750B (zh) | 2018-08-10 | 2023-10-31 | 纳维尔制药有限公司 | Ptpn11（shp2）抑制剂 |
| CR20210175A (es) | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| TW202028183A (zh) * | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| EP3866773B1 (en) | 2018-10-16 | 2024-08-28 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
| BR112021005733A2 (pt) | 2018-10-17 | 2021-07-27 | Array Biopharma Inc. | inibidores de proteína tirosina fosfatase |
| WO2020156243A1 (zh) * | 2019-01-31 | 2020-08-06 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
| CN111647000B (zh) | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| CU20210080A7 (es) | 2019-04-02 | 2022-05-11 | Array Biopharma Inc | Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa |
| JP7586834B2 (ja) | 2019-04-08 | 2024-11-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｈｐ２拮抗薬としてのピリミジノン誘導体 |
| GB201911928D0 (en) | 2019-08-20 | 2019-10-02 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| MX2022003454A (es) | 2019-09-24 | 2022-04-19 | Relay Therapeutics Inc | Inhibidores de fosfatasa shp2 y metodos para su fabricacion y uso. |
| CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
| CA3156359A1 (en) | 2019-11-08 | 2021-05-14 | Adrian Liam Gill | Bicyclic heteroaryl compounds and uses thereof |
| CN114829362A (zh) * | 2019-12-10 | 2022-07-29 | 成都倍特药业股份有限公司 | 一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物 |
| CN117683033A (zh) * | 2019-12-19 | 2024-03-12 | 首药控股(北京)股份有限公司 | 取代的炔基杂环化合物 |
| WO2021143680A1 (zh) * | 2020-01-16 | 2021-07-22 | 浙江海正药业股份有限公司 | 杂芳基类衍生物及其制备方法和用途 |
| CN114846005B (zh) * | 2020-01-21 | 2024-04-02 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| JP2023530838A (ja) * | 2020-06-22 | 2023-07-20 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 置換されたピラジン化合物、当該化合物を含む医薬組成物、及びその使用 |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| CN115028649B (zh) * | 2021-03-05 | 2026-03-17 | 四川科伦博泰生物医药股份有限公司 | 三并环类化合物，包含其的药物组合物及其用途 |
| JP2024516997A (ja) | 2021-05-05 | 2024-04-18 | フヤバイオ インターナショナル，エルエルシー | Ｓｈｐ２阻害剤単独療法およびその使用 |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| KR20240017811A (ko) | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| IL308222A (en) | 2021-05-05 | 2024-01-01 | Huyabio Int Llc | Combination therapies that include SHP2 inhibitors and PD-1 inhibitors |
| CN113248449B (zh) * | 2021-05-06 | 2022-09-23 | 中国药科大学 | 一种含甲脒的芳基螺环类化合物及其制备方法与应用 |
| TW202244049A (zh) * | 2021-05-12 | 2022-11-16 | 大陸商藥雅科技（上海）有限公司 | Shp2磷酸酶抑制劑的製備及其應用 |
| CN115340561A (zh) * | 2021-05-14 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶稠环类抑制剂的制备及其应用 |
| CN115340559A (zh) * | 2021-05-12 | 2022-11-15 | 药雅科技(上海)有限公司 | Shp2磷酸酶杂环类抑制剂的制备及其应用 |
| CN115340545A (zh) * | 2021-05-14 | 2022-11-15 | 浙江海正药业股份有限公司 | 双环杂芳基类衍生物及其制备方法和用途 |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| TW202319056A (zh) * | 2021-07-09 | 2023-05-16 | 南韓商治納輔醫藥科技有限公司 | Ｓｈｐ２抑制劑及其用途 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4573095A1 (en) | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025011568A1 (zh) * | 2023-07-11 | 2025-01-16 | 勤浩医药（苏州）有限公司 | 用作shp2抑制剂的杂环化合物、包含其的药物组合物及其制备方法和用途 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025081291A1 (en) * | 2023-10-16 | 2025-04-24 | Canwell Biotech Limited | Benzo [c] [1, 2] oxaborol-1 (3h) -ol derivatives as shp2 inhibitors, compositions and methods thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10238477A1 (de) * | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| JPWO2004096806A1 (ja) * | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
| US20070219178A1 (en) * | 2003-12-04 | 2007-09-20 | Eisai Co., Ltd. | Preventive or therapeutic agents for multiple sclerosis |
| US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| JP2008521900A (ja) * | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| US8350043B2 (en) * | 2005-06-07 | 2013-01-08 | Pharmacopeia, Inc. | Azinone and diazinone V3 inhibitors for depression and stress disorders |
| JP2009541321A (ja) * | 2006-06-21 | 2009-11-26 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 細胞増殖阻害剤としてのピラジノン |
| WO2008107398A2 (en) * | 2007-03-02 | 2008-09-12 | Basf Se | Pyrazine compounds |
| WO2009049098A2 (en) | 2007-10-09 | 2009-04-16 | Indiana University Research & Technology Corporation | Materials and methods for regulating the activity of phosphatases |
| NZ713361A (en) * | 2009-08-17 | 2017-06-30 | Memorial Sloan Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| CN102080087B (zh) | 2010-12-08 | 2012-05-30 | 厦门大学 | 蛋白酪氨酸磷酸酶shp2的核酸适体及其制备方法 |
| CA2944198C (en) | 2013-04-26 | 2021-11-16 | Indiana University Research & Technology Corporation | Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2) |
| WO2015003094A2 (en) | 2013-07-03 | 2015-01-08 | Indiana University Research & Technology Corporation | Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors |
| AR097631A1 (es) * | 2013-09-16 | 2016-04-06 | Bayer Pharma AG | Trifluorometilpirimidinonas sustituidas con heterociclos y sus usos |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| KR102400920B1 (ko) * | 2014-05-01 | 2022-05-20 | 셀젠 콴티셀 리서치, 인크. | 리신 특이적 데메틸라제-1의 억제제 |
| JP6607870B2 (ja) * | 2014-05-13 | 2019-11-20 | メモリアル スローン ケタリング キャンサー センター | Ｈｓｐ７０モジュレーターならびにその作製および使用方法 |
| DK3160956T3 (da) * | 2014-06-27 | 2020-08-31 | Celgene Quanticel Res Inc | Inhibitorer af lysin-specifik demethylase-1 |
| US10532977B2 (en) | 2015-06-01 | 2020-01-14 | Indiana University Research And Technology Corporation | Small molecule inhibitors of protein tyrosine phosphatases and uses thereof |
| US10287266B2 (en) | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| WO2016203405A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| US9932288B2 (en) | 2015-12-09 | 2018-04-03 | West Virginia University | Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent |
| WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| CN107286150B (zh) | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-杂环类化合物、其中间体、制备方法、药物组合物和应用 |
| MX388576B (es) | 2016-06-07 | 2025-03-20 | Jacobio Pharmaceuticals Co Ltd | Derivados heterociclicos novedosos utiles como inhibidores de shp2. |
| WO2017216706A1 (en) * | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| EP4302834A3 (en) * | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| ES2972741T3 (es) * | 2016-08-10 | 2024-06-14 | Celgene Quanticel Res Inc | Tratamiento del carcinoma de células de Merkel |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| CN108341791B (zh) | 2017-01-23 | 2020-09-29 | 中国科学院上海药物研究所 | 苯并噻二唑类化合物、其制备方法及用途 |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| EA202190196A1 (ru) | 2017-03-23 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| EP3630770B1 (en) | 2017-05-26 | 2024-08-28 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| CN108113984B (zh) | 2017-12-20 | 2021-05-07 | 中国科学院成都生物研究所 | Shp2抑制剂在制备抗肿瘤的药物中的用途 |
| WO2019165073A1 (en) * | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| CN108578395B (zh) | 2018-06-21 | 2019-10-25 | 厦门大学 | 苯丙烯酸类化合物在制备Shp2特异性抑制剂中的用途及其制药用途 |
| CN109646441A (zh) | 2019-01-25 | 2019-04-19 | 上海交通大学医学院附属仁济医院 | Shp-2抑制剂在制备靶向前神经元型胶质瘤的药物中的应用 |
-
2019
- 2019-03-18 RU RU2020133727A patent/RU2020133727A/ru unknown
- 2019-03-18 JP JP2020550667A patent/JP7265275B2/ja active Active
- 2019-03-18 EP EP19771115.3A patent/EP3768664B1/en active Active
- 2019-03-18 AU AU2019239658A patent/AU2019239658A1/en not_active Abandoned
- 2019-03-18 US US16/356,360 patent/US10561655B2/en active Active
- 2019-03-18 KR KR1020207030224A patent/KR102724968B1/ko active Active
- 2019-03-18 WO PCT/US2019/022717 patent/WO2019182960A1/en not_active Ceased
- 2019-03-18 CA CA3097709A patent/CA3097709A1/en not_active Abandoned
- 2019-03-18 TW TW108109165A patent/TW201940167A/zh unknown
- 2019-03-18 CN CN201980031603.9A patent/CN112368272B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518395A5 (https=) | ||
| RU2020133727A (ru) | Ингибиторы shp2 и их применение | |
| AU2019359885B2 (en) | Protein tyrosine phosphatase inhibitors | |
| JP2020522570A5 (https=) | ||
| HRP20120105T1 (hr) | Aminoheterociklički spojevi | |
| AU2015279984B2 (en) | Mnk inhibitors and methods related thereto | |
| WO2021061515A1 (en) | Shp2 inhibitors and uses thereof | |
| JP2022504936A5 (https=) | ||
| KR101812357B1 (ko) | Ｃｄｋ4/6의 억제제로서의 피롤로피리미딘 화합물 | |
| JP2023520759A5 (https=) | ||
| JP2021528466A5 (https=) | ||
| JP2021519291A5 (https=) | ||
| KR20150036044A (ko) | Fgfr 억제제로서 치환된 트리사이클릭 화합물 | |
| RU2015131148A (ru) | СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ | |
| JP2016500671A5 (https=) | ||
| MX2011001196A (es) | Compuestos de pirimidina, composiciones y metodos de uso. | |
| RU2020124116A (ru) | Производные арил-бипиридинамина в качестве ингибиторов фосфатидилинозитолфосфаткиназы | |
| RU2006129307A (ru) | Терапевтические комбинации атипичных нейролептиков с антагонистами кортикотропин-рилизинг фактора | |
| RU2006140070A (ru) | Конденсированные производные пиримидина, применимые в качестве антагонистов аденозинового рецептора a2b | |
| TW202016105A (zh) | 用於治療自體免疫疾病的新穎雜芳基雜環基化合物 | |
| KR20140059195A (ko) | 트리시클릭 헤테로시클릭 화합물 및 jak 저해제 | |
| JP2021504380A5 (https=) | ||
| WO2024193683A1 (en) | Bicyclic derivatives, compositions and uses thereof | |
| Ibrahim et al. | Heterocyclization with Some Heterocyclic Diamines: Synthetic Approaches for Nitrogen Bridgehead Heterocyclic Systems | |
| WO2022167682A1 (en) | Azabicyclic shp2 inhibitors |